Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 15/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 15/20 | 0.50 |
| ▸ | PDE2A | O00408 | 2/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20703662 | 0.83 | KDM4E (0.51) | NOS1NOS2KDM4EKMT2AADORA2A | |
| SCHEMBL29598934 | 0.83 | KDM4E (0.51) | NOS1NOS2KDM4EKMT2AADORA2A | |
| SCHEMBL11236532 | 0.77 | PDE3B (0.49) | PDE3BPDE3APDE2AP2RY12 | |
| SCHEMBL1586090 | 0.77 | PDE3B (0.47) | PDE3BPDE3APDE2AP2RY12TYRO3 | |
| SCHEMBL2271318 | 0.76 | NOS1 (0.44) | PDE3BPDE3APDE2AP2RY12NOS1 | |
| SCHEMBL17731751 | 0.75 | SIRT2 (0.60) | NOS1NOS2KDM4EKMT2AADORA2A | |
| SCHEMBL5786187 | 0.75 | SIRT2 (0.60) | PDE3BPDE3APDE2AP2RY12TYRO3 | |
| SCHEMBL1163700 | 0.75 | SIRT2 (0.64) | PDE3BPDE3APDE2AP2RY12TYRO3 | |
| SCHEMBL16939766 | 0.75 | PDE3B (0.44) | PDE3BPDE3APDE2AP2RY12TYRO3 | |
| SCHEMBL11236470 | 0.72 | PDE3B (0.48) | PDE3BPDE3APDE2AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011034741-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-24 | — | — | WO | claimed |
| US-20210238176-A1 | PESTICIDALLY-ACTIVE BICYCLIC HETEROAROMATIC COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2021-08-05 | — | — | US | disclosed |
| US-20210238176-A1 | PESTICIDALLY-ACTIVE BICYCLIC HETEROAROMATIC COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2021-08-05 | — | — | US | disclosed |
| EP-3833663-A1 | PESTICIDALLY-ACTIVE BICYCLIC HETEROAROMATIC COMPOUNDS | Syngenta Crop Protection AG (CH) | 2021-06-16 | — | — | EP | disclosed |
| CN-112585137-A | Pesticidally active bicyclic heteroaromatic compounds | 先正达农作物保护股份公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020030503-A1 | PESTICIDALLY-ACTIVE BICYCLIC HETEROAROMATIC COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020030503-A1 | PESTICIDALLY-ACTIVE BICYCLIC HETEROAROMATIC COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2020-02-13 | — | — | WO | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-9447134-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150210727-A1 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-8273752-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-09-25 | — | — | US | disclosed |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | PDE3B 4693/4885PDE3A 4572/4885PDE2A 4615/4885 |
| US-20150210727-A1 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | IMPDH1, IMPDH2, IMPA1 | PDE3B 245/4885PDE3A 208/4885PDE2A 262/4885 |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | TYMP, DPYD, THPO | PDE3B 2143/4885PDE3A 1963/4885PDE2A 2280/4885 |
| US-20210238176-A1 | PESTICIDALLY-ACTIVE BICYCLIC HETEROAROMATIC COMPOUNDS | DDT, ACHE, CYP1B1 | PDE3B 1456/4885PDE3A 906/4885PDE2A 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.